Cite
HARVARD Citation
Conlon, N. et al. (n.d.). Neratinib plus dasatinib has pre-clinical efficacy against HER2-positive breast cancer. European journal of cancer. pp. S64-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Conlon, N. et al. (n.d.). Neratinib plus dasatinib has pre-clinical efficacy against HER2-positive breast cancer. European journal of cancer. pp. S64-. [Online].